
LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC
LB2102, a DLL3-directed autologous CAR T-cell therapy, was well tolerated without any dose-limiting toxicities (DLTs) observed up to dose level 4 (DL4), and it demonstrated preliminary antitumor activity in patients with relapsed/refractory small cell …